Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers | Zendy

Hatsushi Yamagishi | Zendy; Tomoyuki Koike | Zendy; Shuichi Ohara | Zendy; Toru Horii | Zendy; Ryousuke Kikuchi | Zendy; Shigeyuki Kobayashi | Zendy; Yasuhiko Abe | Zendy; Katsunori Iijima | Zendy; Akira Imatani | Zendy; Kaori Suzuki | Zendy; Takanori Hishinuma | Zendy; Junichi Goto | Zendy; Tooru Shimosegawa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers

Author(s) -

Hatsushi Yamagishi,

Tomoyuki Koike,

Shuichi Ohara,

Toru Horii,

Ryousuke Kikuchi,

Shigeyuki Kobayashi,

Yasuhiko Abe,

Katsunori Iijima,

Akira Imatani,

Kaori Suzuki,

Takanori Hishinuma,

Junichi Goto,

Tooru Shimosegawa

Publication year - 2008

Publication title -

world journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.427

H-Index - 155

eISSN - 2219-2840

pISSN - 1007-9327

DOI - 10.3748/wjg.14.2049

Subject(s) - lansoprazole , rabeprazole , cyp2c19 , pharmacology , omeprazole , medicine , gastric acid , drug , oral administration , chemistry , gastroenterology , stomach , cytochrome p450 , metabolism

To compare rabeprazole (RPZ; 10 mg) with Lansoprazole orally disintegrating tablets (LPZ; 30 mg OD) in terms of antisecretory activity and blood drug concentration after a single dose.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research